CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 14 enrolled
Drug / intervention
Donepezildrug
Likely dose
Donepezil 5 milligrams a day for 6 weeksAI-extracted
Key inclusion· 6
  • Prior diagnosis of primary brain tumor
  • Underwent fractionated radiotherapy (≥23.4 Gy) with or without surgery or chemotherapy for the brain tumor at least 1 year ago
  • Karnofsky or Lansky performance status 70-100%
  • Baseline IQ ≥70 on Peabody Picture Vocabulary Test-3
Key exclusion· 9
  • No type 2 neurofibromatosis
  • Stereotactic radiosurgery as sole treatment
  • Evidence of disease progression by MRI
  • Pregnant or nursing

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00452868
NCT00452868Early Ph 1Completed

A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation

Wake Forest University Health Sciences·interventional·Posted Mar 28, 2007·Updated Sep 7, 2018

In Brief

A Early Phase 1 clinical trial evaluating Donepezil for Brain and Central Nervous System Tumors and 5 related conditions. Completed, enrolled 14 participants across 2 sites.

Detailed Summary

RATIONALE: Donepezil may decrease the side effects caused by radiation therapy to the brain. PURPOSE: This clinical trial is studying how well donepezil works in treating young patients with primary brain tumors previously treated with radiation therapy to the brain.

Study Details

Timeline

Early Ph 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 28, 2007
Enrollment StartJun 1, 2006
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.3 years ago

Interventions

Donepezildrug

Donepezil 5 milligrams a day for 6 weeks